Docetaxel boosts response to chemotherapy in patients with early breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1223, 2000-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab boosts chemotherapy response in breast cancer

By  

Inpharma, Vol. 1, Iss. 1377, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

A deletion in chromosome 11q may predict the response to anthracycline-based chemotherapy in patients with early node-negative breast cancer

By  

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Docetaxel regimen improves survival in early breast cancer

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Docetaxel delivers over doxorubicin for early breast cancer

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Gemcitabine/epirubicin/docetaxel effective in early breast cancer

By  

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite